Top

Published in:

Open Access 01-06-2018 | Commentary

Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical

Authors: Gregory J. Bix, Justin F. Fraser, William J. Mack, S. Thomas Carmichael, Miguel Perez-Pinzon, Halina Offner, Lauren Sansing, Francesca Bosetti, Cenk Ayata, Keith R. Pennypacker

Published in: Translational Stroke Research | Issue 3/2018

Abstract

The first annual Stroke Translational Research Advancement Workshop (STRAW), entitled “Uncovering the Rosetta Stone: Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical” was held at the University of Kentucky on October 4–5, 2017. This workshop was organized by the Center for Advanced Translational Stroke Science. The workshop consisted of 2 days of activities. These included three presentations establishing the areas of research in stroke therapeutics, discussing the routes for translation from bench to bedside, and identifying successes and failures in the field. On day 2, grant funding opportunities and goals for the National Institute for Neurological Diseases and Stroke were presented. In addition, the meeting also included break-out sessions designed to connect researchers in areas of stroke, and to foster potential collaborations. Finally, the meeting concluded with an open discussion among attendees led by a panel of experts.

Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285–95. https://doi.org/10.1056/NEJMoa1415061.CrossRefPubMed

Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360. https://doi.org/10.1161/CIR.0000000000000350.CrossRef

Thacker C. Stroke falls to no. 5 cause of death in U.S. Am Heart Assoc Media Alert. 2014.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7. https://doi.org/10.1056/NEJM199512143332401.CrossRef

Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18. https://doi.org/10.1056/NEJMoa1414792.CrossRefPubMed

Stroke Therapy Academic Industry R. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.CrossRef

Bath P. Re: Stroke therapy academic industry roundtable II (STAIR-II). Stroke. 2002;33(2):639–40.PubMedCrossRef

Fisher M, Hanley DF, Howard G, Jauch EC, Warach S, Group S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007;38(2):245–8. https://doi.org/10.1161/01.STR.0000255951.37434.aa.CrossRefPubMed

Thomas A, Detilleux J, Flecknell P, Sandersen C. Impact of Stroke Therapy Academic Industry Roundtable (STAIR) guidelines on peri-anesthesia care for rat models of stroke: a meta-analysis comparing the years 2005 and 2015. PLoS One. 2017;12(1):e0170243. https://doi.org/10.1371/journal.pone.0170243.CrossRefPubMedPubMedCentral

10.

Bosetti F, Koenig JI, Ayata C, Back SA, Becker K, Broderick JP, et al. Translational stroke research: vision and opportunities. Stroke. 2017;48(9):2632–7. https://doi.org/10.1161/STROKEAHA.117.017112.CrossRefPubMedPubMedCentral

11.

Saver JL. Time is brain—quantified. Stroke. 2006;37(1):263–6. https://doi.org/10.1161/01.STR.0000196957.55928.ab.CrossRefPubMed

12.

Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947. https://doi.org/10.1161/STR.0b013e318284056a.CrossRefPubMed

13.

Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38(3):948–54. https://doi.org/10.1161/01.STR.0000257304.21967.ba.CrossRefPubMed

14.

Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41(10):2254–8. https://doi.org/10.1161/STROKEAHA.110.592535.CrossRefPubMed

15.

Khatri P, Abruzzo T, Yeatts SD, Nichols C, Broderick JP, Tomsick TA, et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009;73(13):1066–72. https://doi.org/10.1212/WNL.0b013e3181b9c847.CrossRefPubMedPubMedCentral

16.

Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20. https://doi.org/10.1056/NEJMoa1411587.CrossRefPubMed

17.

Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30. https://doi.org/10.1056/NEJMoa1414905.CrossRefPubMed

18.

Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. AHA/ASA focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:3020–35. https://doi.org/10.1161/STR.0000000000000074.CrossRefPubMed

19.

Pride GL, Fraser JF, Gupta R, Alberts MJ, Rutledge JN, Fowler R, et al. Prehospital care delivery and triage of stroke with emergent large vessel occlusion (ELVO): report of the Standards and Guidelines Committee of the Society of Neurointerventional Surgery. J Neurointerv Surg. 2017;9(8):802–12. https://doi.org/10.1136/neurintsurg-2016-012699.CrossRefPubMed

20.

Gandhi CD, Al Mufti F, Singh IP, Abruzzo T, Albani B, Ansari SA, et al. Neuroendovascular management of emergent large vessel occlusion: update on the technical aspects and standards of practice by the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery. J Neurointerv Surg. 2018;10:315–20. https://doi.org/10.1136/neurintsurg-2017-013554.CrossRefPubMed

21.

Albers GW, Lansberg MG, Kemp S, Tsai JP, Lavori P, Christensen S, et al. A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3). Int J Stroke. 2017;12(8):896–905. https://doi.org/10.1177/1747493017701147.CrossRefPubMedPubMedCentral

22.

Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21. https://doi.org/10.1056/NEJMoa1706442.CrossRefPubMed

23.

Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–31. https://doi.org/10.1016/S0140-6736(16)00163-X.CrossRefPubMed

24.

Adeoye O, Albright KC, Carr BG, Wolff C, Mullen MT, Abruzzo T, et al. Geographic access to acute stroke care in the United States. Stroke. 2014;45(10):3019–24. https://doi.org/10.1161/STROKEAHA.114.006293.CrossRefPubMedPubMedCentral

25.

Hanks N, Wen G, He S, Song S, Saver JL, Cen S, et al. Expansion of U.S. emergency medical service routing for stroke care: 2000–2010. West J Emerg Med. 2014;15(4):499–503. https://doi.org/10.5811/westjem.2014.2.20388.CrossRefPubMedPubMedCentral

26.

Prabhakaran S, Ward E, John S, Lopes DK, Chen M, Temes RE, et al. Transfer delay is a major factor limiting the use of intra-arterial treatment in acute ischemic stroke. Stroke. 2011;42(6):1626–30. https://doi.org/10.1161/STROKEAHA.110.609750.CrossRefPubMed

27.

Sun CH, Nogueira RG, Glenn BA, Connelly K, Zimmermann S, Anda K, et al. “Picture to puncture”: a novel time metric to enhance outcomes in patients transferred for endovascular reperfusion in acute ischemic stroke. Circulation. 2013;127(10):1139–48. https://doi.org/10.1161/CIRCULATIONAHA.112.000506.CrossRefPubMed

28.

Grupke S, Hall J, Dobbs M, Bix GJ, Fraser JF. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview. Clin Neurol Neurosurg. 2015;129:1–9. https://doi.org/10.1016/j.clineuro.2014.11.013.CrossRefPubMed

29.

Babadjouni RM, Walcott BP, Liu Q, Tenser MS, Amar AP, Mack WJ. Neuroprotective delivery platforms as an adjunct to mechanical thrombectomy. Neurosurg Focus. 2017;42(4):E4. https://doi.org/10.3171/2017.1.FOCUS16514.CrossRefPubMed

30.

Fraser JF, Maniskas M, Trout A, Lukins D, Parker L, Stafford WL, et al. Intra-arterial verapamil post-thrombectomy is feasible, safe, and neuroprotective in stroke. J Cereb Blood Flow And Metab. 2017;37:3531–43. https://doi.org/10.1177/0271678X17705259.CrossRef

31.

Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372(6):528–36. https://doi.org/10.1056/NEJMoa1408827.CrossRefPubMedPubMedCentral

32.

Babadjouni RM, Radwanski RE, Walcott BP, Patel A, Durazo R, Hodis DM, et al. Neuroprotective strategies following intraparenchymal hemorrhage. J Neurointerv Surg. 2017;9(12):1202–7. https://doi.org/10.1136/neurintsurg-2017-013197.CrossRefPubMed

33.

Righy C, Bozza MT, Oliveira MF, Bozza FA. Molecular, cellular and clinical aspects of intracerebral hemorrhage: are the enemies within? Curr Neuropharmacol. 2016;14(4):392–402.CrossRefPubMedPubMedCentral

34.

Kellner CP, Connolly ES Jr. Neuroprotective strategies for intracerebral hemorrhage: trials and translation. Stroke. 2010;41(10 Suppl):S99–102. https://doi.org/10.1161/STROKEAHA.110.597476.CrossRefPubMed

35.

Kathirvelu B, Carmichael ST. Intracerebral hemorrhage in mouse models: therapeutic interventions and functional recovery. Metab Brain Dis. 2015;30(2):449–59. https://doi.org/10.1007/s11011-014-9559-7.CrossRefPubMed

36.

Mould WA, Carhuapoma JR, Muschelli J, Lane K, Morgan TC, McBee NA, et al. Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke. 2013;44(3):627–34. https://doi.org/10.1161/STROKEAHA.111.000411.CrossRefPubMedPubMedCentral

37.

Hanley DF, Thompson RE, Muschelli J, Rosenblum M, McBee N, Lane K, et al. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. The Lancet Neurology. 2016;15(12):1228–37. https://doi.org/10.1016/S1474-4422(16)30234-4.CrossRefPubMedPubMedCentral

38.

Hanggi D, Etminan N, Aldrich F, Steiger HJ, Mayer SA, Diringer MN, et al. Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage]). Stroke. 2017;48(1):145–51. https://doi.org/10.1161/STROKEAHA.116.014250.CrossRefPubMed

39.

Narayanan SV, Dave KR, Saul I, Perez-Pinzon MA. Resveratrol preconditioning protects against cerebral ischemic injury via nuclear erythroid 2-related factor 2. Stroke. 2015;46(6):1626–32. https://doi.org/10.1161/STROKEAHA.115.008921.CrossRefPubMedPubMedCentral

40.

Morris GP, Wright AL, Tan RP, Gladbach A, Ittner LM, Vissel B. A comparative study of variables influencing ischemic injury in the Longa and Koizumi methods of intraluminal filament middle cerebral artery occlusion in mice. PLoS One. 2016;11(2):e0148503. https://doi.org/10.1371/journal.pone.0148503.CrossRefPubMedPubMedCentral

41.

Waxham MN, Grotta JC, Silva AJ, Strong R, Aronowski J. Ischemia-induced neuronal damage: a role for calcium/calmodulin-dependent protein kinase II. J Cereb Blood Flow Metab. 1996;16(1):1–6. https://doi.org/10.1097/00004647-199601000-00001.CrossRefPubMed

42.

Sharkey J, Ritchie IM, Kelly PA. Perivascular microapplication of endothelin-1: a new model of focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab. 1993;13(5):865–71. https://doi.org/10.1038/jcbfm.1993.108.CrossRefPubMed

43.

Defazio RA, Levy S, Morales CL, Levy RV, Dave KR, Lin HW, et al. A protocol for characterizing the impact of collateral flow after distal middle cerebral artery occlusion. Transl Stroke Res. 2011;2(1):112–27. https://doi.org/10.1007/s12975-010-0044-2.CrossRefPubMedPubMedCentral

44.

Leonardo CC, Robbins S, Dore S. Translating basic science research to clinical application: models and strategies for intracerebral hemorrhage. Front Neurol. 2012;3:85. https://doi.org/10.3389/fneur.2012.00085.CrossRefPubMedPubMedCentral

45.

MacLellan CL, Silasi G, Auriat AM, Colbourne F. Rodent models of intracerebral hemorrhage. Stroke. 2010;41(10 Suppl):S95–8.CrossRefPubMed

46.

Bederson JB, Germano IM, Guarino L. Cortical blood flow and cerebral perfusion pressure in a new noncraniotomy model of subarachnoid hemorrhage in the rat. Stroke. 1995;26(6):1086–91. discussion 91-2CrossRefPubMed

47.

Rehni AK, Liu A, Perez-Pinzon MA, Dave KR. Diabetic aggravation of stroke and animal models. Exp Neurol. 2017;292:63–79. https://doi.org/10.1016/j.expneurol.2017.03.004.CrossRefPubMedPubMedCentral

48.

Riley G, Syeda F, Kirchhof P, Fabritz L. An introduction to murine models of atrial fibrillation. Front Physiol. 2012;3:296. https://doi.org/10.3389/fphys.2012.00296.PubMedPubMedCentralCrossRef

49.

de Rivero Vaccari JP, Patel HH, Brand FJ 3rd, Perez-Pinzon MA, Bramlett HM, Raval AP. Estrogen receptor beta signaling alters cellular inflammasomes activity after global cerebral ischemia in reproductively senescence female rats. J Neurochem. 2016;136(3):492–6. https://doi.org/10.1111/jnc.13404.CrossRefPubMed

50.

Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011;42(9):2645–50. https://doi.org/10.1161/STROKEAHA.111.618850.CrossRefPubMed

51.

Stem Cell Therapies as an Emerging Paradigm in Stroke P. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009;40(2):510–5. https://doi.org/10.1161/STROKEAHA.108.526863.CrossRef

52.

Savitz SI, Cramer SC, Wechsler L, Consortium S. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke. 2014;45(2):634–9. https://doi.org/10.1161/STROKEAHA.113.003379.CrossRefPubMed

53.

Walker MF, Hoffmann TC, Brady MC, Dean CM, Eng JJ, Farrin AJ, et al. Improving the development, monitoring and reporting of stroke rehabilitation research: consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabil Neural Repair. 2017;31(10–11):877–84. https://doi.org/10.1177/1545968317732686.CrossRefPubMed

54.

Neumann JT, Cohan CH, Dave KR, Wright CB, Perez-Pinzon MA. Global cerebral ischemia: synaptic and cognitive dysfunction. Curr Drug Targets. 2013;14(1):20–35.CrossRefPubMedPubMedCentral

55.

Dirnagl U, Lauritzen M. Fighting publication bias: introducing the negative results section. J Cereb Blood Flow Metab. 2010;30(7):1263–4. https://doi.org/10.1038/jcbfm.2010.51.CrossRefPubMed

56.

Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014;505(7485):612–3.CrossRefPubMedPubMedCentral

57.

Sinha S, Subramanian S, Emerson-Webber A, Lindner M, Burrows GG, Grafe M, et al. Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J NeuroImmune Pharmacol. 2010;5(2):231–9. https://doi.org/10.1007/s11481-009-9175-1.CrossRefPubMed

58.

Offner H. Modeling immunity and inflammation in stroke: don’t be afraid of mice? Stroke. 2014;45(9):e181–2. https://doi.org/10.1161/STROKEAHA.114.005642.CrossRefPubMedPubMedCentral

59.

Ren X, Akiyoshi K, Grafe MR, Vandenbark AA, Hurn PD, Herson PS, et al. Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity. Metab Brain Dis. 2012;27(1):7–15.CrossRefPubMed

60.

Dotson AL, Zhu W, Libal N, Alkayed NJ, Offner H. Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy. Front Cell Neurosci. 2014;8:284.CrossRefPubMedPubMedCentral

61.

Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244–50. https://doi.org/10.1161/STROKEAHA.108.541128.CrossRefPubMedPubMedCentral

62.

Wang J, Ye Q, Xu J, Benedek G, Zhang H, Yang Y, et al. DRalpha1-MOG-35-55 reduces permanent ischemic brain injury. Transl Stroke Res. 2017;8(3):284–93. https://doi.org/10.1007/s12975-016-0514-2.CrossRefPubMed

63.

Gadhia J, Starkman S, Ovbiagele B, Ali L, Liebeskind D, Saver JL. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke. 2010;41(2):300–6. https://doi.org/10.1161/STROKEAHA.109.566935.CrossRefPubMedPubMedCentral

64.

Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985;230(4731):1289–92.CrossRefPubMed

65.

Zivin JA, Lyden PD, DeGirolami U, Kochhar A, Mazzarella V, Hemenway CC, et al. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol. 1988;45(4):387–91.CrossRefPubMed

66.

Bederson JB, Awad IA, Wiebers DO, Piepgras D, Haley EC Jr, Brott T, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2000;31(11):2742–50.CrossRefPubMed

67.

Geremia G, Haklin M, Brennecke L. Embolization of experimentally created aneurysms with intravascular stent devices. AJNR Am J Neuroradiol. 1994;15(7):1223–31.PubMed

68.

Sadasivan C, Cesar L, Seong J, Rakian A, Hao Q, Tio FO, et al. An original flow diversion device for the treatment of intracranial aneurysms: evaluation in the rabbit elastase-induced model. Stroke. 2009;40(3):952–8. https://doi.org/10.1161/STROKEAHA.108.533760.CrossRefPubMedPubMedCentral

69.

Wakhloo AK, Schellhammer F, de Vries J, Haberstroh J, Schumacher M. Self-expanding and balloon-expandable stents in the treatment of carotid aneurysms: an experimental study in a canine model. AJNR Am J Neuroradiol. 1994;15(3):493–502.PubMed

70.

Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with urokinase in a canine model: part 1. Canine intraventricular blood cast model. Neurosurgery. 1986;19(4):540–6.CrossRefPubMed

71.

Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017;389(10069):603–11. https://doi.org/10.1016/S0140-6736(16)32410-2.CrossRefPubMedPubMedCentral

72.

Fam MD, Hanley D, Stadnik A, Zeineddine HA, Girard R, Jesselson M, et al. Surgical performance in minimally invasive surgery plus recombinant tissue plasminogen activator for intracerebral hemorrhage evacuation phase III clinical trial. Neurosurgery. 2017;81(5):860–6. https://doi.org/10.1093/neuros/nyx123.PubMedCrossRef

73.

Askenase MH, Sansing LH. Stages of the inflammatory response in pathology and tissue repair after intracerebral hemorrhage. Semin Neurol. 2016;36(3):288–97. https://doi.org/10.1055/s-0036-1582132.CrossRefPubMedPubMedCentral

74.

Chang CF, Goods BA, Askenase MH, Hammond MD, Renfroe SC, Steinschneider AF, et al. Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. J Clin Invest. 2017;128:607–24. https://doi.org/10.1172/JCI95612.CrossRefPubMedPubMedCentral

Title: Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical
Authors: Gregory J. Bix
Justin F. Fraser
William J. Mack
S. Thomas Carmichael
Miguel Perez-Pinzon
Halina Offner
Lauren Sansing
Francesca Bosetti
Cenk Ayata
Keith R. Pennypacker
Publication date: 01-06-2018
Publisher: Springer US
Published in: Translational Stroke Research / Issue 3/2018
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-018-0628-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Factors Mediating Outcome After Stroke: Gender, Thrombolysis, and Their Interaction

Correction to: Pre-existing Small Vessel Disease in Patients with Acute Stroke from the Middle East, Southeast Asia, and Philippines

Treatment with the PPARγ Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats

Significance of Mitochondrial Protein Post-translational Modifications in Pathophysiology of Brain Injury

Cerebral Hypoperfusion and Other Shared Brain Pathologies in Ischemic Stroke and Alzheimer’s Disease

Disease of mRNA Regulation: Relevance for Ischemic Brain Injury